

1 **Per vaginal bleeding-an important but ignored feature of dengue**

2 Ananda Wijewickrama¹, Heshan Kuruppu², Damayanthi Idampitiya¹, Rivindu Wickramanayake²,
3 Anagi Kottahachchi², Jeewantha Jayamali², Padukkage Harshani Chathurangika², Nushara
4 Senatilleke¹, Navanjana Warnakulasuriya¹, Chandima Jeewandara², Gathsaurie Neelika
5 Malavige^{2*}

6

7 ¹ National Institute of Infectious Diseases, Angoda, Sri Lanka.

8 ²Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular
9 Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

10

11 **Corresponding author information:**

12 *Prof. Neelika Malavige DPhil (Oxon), FRCP (Lond), FRCPath (UK)

13 Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine,
14 Faculty of Medical Sciences, University of Sri Jayawardanapura, Sri Lanka.

15 Tel +94 (0) 772443193; Email: gathsaurie.malavige@ndm.ox.ac.uk

16

17

18

19

20 **Abstract**

21 **Background:** Elderly individuals, those with comorbidities and pregnant women are at a higher
22 risk of developing severe dengue and succumbing to their illness. However, an increased incidence
23 of severe dengue and fatalities are seen in females of the reproductive age. As per vaginal (PV)
24 bleeding is an important complication that has not been well characterized, we sought to determine
25 the frequency, complications and disease outcomes in women who develop PV bleeding.

26 **Methodology/Principal findings:** 288 adult female patients were recruited from the National
27 Institute of Infectious Diseases Sri Lanka. All clinical features and laboratory investigations were
28 recorded throughout the duration of hospital admission along with treatment received.

29 28/288 (9.72%) reported PV bleeding, with 12/28 (42.85%) developing dengue haemorrhagic fever
30 (DHF) compared to 65/260 (25%) of those who did not have bleeding.

31 Women who developed PV bleeding were more likely to have developed DHF (OR 2.2, 95% CI
32 0.98 to 5.1, $p=0.06$), abdominal pain (OR=2.17, 95% CI = 0.99 to 4.69, $p = 0.06$), vomiting (OR=
33 2.0, 95% CI= 0.89 to 4.44, $p= 0.10$), diarrhoea (OR= 4.35, 95% CI = 1.908 to 9.610, $p= 0.0004$) or
34 evidence of any fluid leakage (OR= 1.98, 95% CI = 0.91 to 4.5, $p = 0.11$). Although not significant,
35 those who had PV bleeding were more likely to have been given intravenous fluids, blood
36 transfusions and colloids.

37 **Conclusions:** PV bleeding appears to associate with worse disease outcomes. The possible
38 contribution of PV bleeding to higher incidence of severe dengue and fatality rates observed in
39 many countries, should be further investigated.

40

41 **Author summary**

42 Elderly individuals, those with comorbidities and pregnant women are at a higher risk of
43 developing severe dengue and succumbing to their illness. However, an increased incidence of
44 severe dengue and fatalities are seen in females of the reproductive age. As per vaginal (PV)
45 bleeding is an important complication that has not been well characterized, we investigated the
46 complications and disease outcomes in women who developed PV bleeding, by studying clinical
47 and laboratory characteristics of 288 women with acute dengue. 28 (9.72%) reported PV bleeding,
48 with 42.85% developing dengue haemorrhagic fever (DHF). Women who developed PV bleeding
49 were more likely to have developed DHF, abdominal pain, vomiting, diarrhoea or evidence of any
50 fluid leakage. They were more likely to have been given intravenous fluids, blood transfusions and
51 colloids. Therefore, the possible contribution of PV bleeding to higher incidence of severe dengue
52 and fatality rates in many countries should be further investigated.

53

54

55

56

57

58

59

60

61 **Introduction**

62 Dengue was named as one of the top ten threats to global health by the World Health Organization
63 in 2019 [1]. Since then the number of cases has increased exponentially with over 10 million cases
64 being reported in the first six months of 2024 [2]. Dengue is also the only infectious disease where
65 the annual mortality rates are rising, with case fatality rates (CFRs) increasing during outbreaks
66 due to overwhelming of health care systems [2]. Apart from the rise in the number of cases, there
67 has been a gradual shift in the age of infection, with many countries reporting most cases among
68 adults [3, 4]. As a result, more infections occur in older individuals, in those with comorbidities
69 and in women in reproductive age group, some who are pregnant. Infection in older individuals,
70 in those with comorbidities and in pregnancy is known to associate with severe dengue with higher
71 risk of fatalities [5-7]. In the absence of a specific treatment and prognostic biomarkers, increase
72 in infections in vulnerable populations leads a larger proportion of patients developing severe
73 dengue, burdening fragile health care systems.

74

75 Although most individuals with dengue experience a mild illness, some develop plasma leakage
76 leading to pleural effusions, ascites, shock, organ dysfunction and severe bleeding [8]. Liver
77 dysfunction, shock, extremes of age, pregnancy and the presence of comorbidities such as diabetes
78 have been identified as risk factors for death due to dengue [9-11]. In addition, females have also
79 shown to be at a higher risk of developing severe disease with higher case fatality rates than males
80 [6, 12, 13]. For instance, although 62% of patients who were hospitalized due to dengue in
81 Bangladesh were males, 58% who succumbed to the illness were females [13]. Furthermore, in
82 Brazil, although most deaths were seen in individuals >70 years of age, among 20- to 49-year-

83 olds, more deaths were seen among females compared to males [5]. In Sri Lanka, although the
84 CFRs due to dengue has markedly reduced over the years (currently 0.05%), in 2024, 19/22
85 (86.4%) of those who succumbed to the illness were females [14]. 13/19 (68.4%) deaths in women
86 were in those between 15 to 45 years of age [14].

87

88 The reasons for a higher incidence of severe dengue and higher mortality among women of the
89 reproductive age groups are not known. These could be due to late presentation to a health care
90 facility due to differences in health seeking behavior among men and women, women presenting
91 to hospital late due to carer responsibilities or because women develop complications due to
92 dengue, more frequently than males. Although gastrointestinal bleeding manifestations are less
93 frequent among dengue patients in Sri Lanka in recent years, due to early detection of plasma
94 leakage and timely fluid replacement, women still develop per vaginal (PV) bleeding during
95 dengue [15, 16]. Due to the limited data on the frequency of PV bleeding in women with dengue
96 and associated complications and disease outcomes, we proceeded to characterize the frequency
97 and disease severity in a large cohort of female patients with dengue in Sri Lanka.

98

99

100

101

102

103

104 **Methods**

105 **Patients with acute dengue**

106 288, female patients aged over 18 years of age, who were admitted to the National Institute of
107 Infectious Disease, for management of a probable dengue infection were recruited following
108 informed written consent from November 2021 to October 2024. An acute dengue infection was
109 confirmed in them by either a rapid dengue NS1 antigen test (SD Biosensor, South Korea) or a
110 quantitative PCR assay [17]. All patients were followed up from the time of admission to discharge
111 from hospital and clinical and laboratory features including dengue warning signs and bleeding
112 manifestations were recorded daily. The liver transaminases and C-reactive protein levels were
113 recorded at the time of admission to hospital.

114

115 Abdominal ultrasound scans were done to assess the presence of fluid leakage in the form of
116 pleural effusions or ascites in all patients at the time of admission and twice a day after that,
117 throughout the period while they were in hospital, if they did not have features of plasma leakage
118 in the initial scan. The treatment received including administration of fluid boluses, colloids and
119 blood products was also recorded from their clinical records. The duration of hospital stay was
120 recorded from time to admission to discharge.

121

122 Disease severity was classified according to the 2011 World Health Organization (WHO) dengue
123 diagnostic criteria for dengue based on the disease progression while they were in hospital [18].
124 Accordingly, patients with a rise in haematocrit >20% of the baseline together with
125 thrombocytopenia with accompanying bleeding manifestations, or those who had ultrasound scan

126 evidence of plasma leakage were classified as having DHF. Shock was defined as the presence of
127 a narrowing pulse pressure of 20 mm Hg in patients with DHF. According to the above criteria,
128 77 were classified as having DHF, and 211 patients as DF.

129

130 **Ethics approval**

131 Ethical approval was obtained from the Ethics Review Committee of the Faculty of Medical
132 Sciences, University of Sri Jayewardenepura (ethics application number:58/19). All patients gave
133 informed written consent to participate in the study.

134

135 **Statistical analysis**

136 Statistical analysis was carried out using GraphPad PRISM version 10.3.1. The degree of
137 associations between disease severity and clinical and demographic characteristics, was expressed
138 as the odds ratio (OR), which was obtained from standard contingency table analysis by Haldane's
139 modification of Woolf's method. Chi Square tests or the Fisher's exact test was used to determine
140 the p value.

141

142

143

144

145

146

147

148

149 **Results**

150 Of the 288 females recruited, 28 (9.72%) reported to have per vaginal bleeding, while 260
151 (90.27%) did not develop any bleeding manifestations. 77 (26.73%) of them were classified as
152 DHF. 12/28 (42.85%) of those with PV bleeding had DHF, while 16, were classified as having
153 DF, due to the absence of fluid leakage in repeated abdominal ultrasound scans. Therefore, women
154 who developed PV bleeding were more likely to have developed DHF (OR 2.2, 95% CI 0.98 to
155 5.1, $p=0.06$). The clinical and laboratory features of the females with and without PV bleeding is
156 shown in table 1. The women who had bleeding PV did not have any other overt bleeding
157 manifestation.

158

159 The duration of illness at the time of presentation for the patients was a median of 4 (IQR 3 to 4
160 Days). There was no significant difference ($p= 0.64$) in the day of presentation to hospital in those
161 with bleeding PV (median 4, IQR 3 to 4) compared to those who had no bleeding (median 4, IQR
162 3 to 4). Those with PV bleeding were more likely to have abdominal pain (OR=2.17, 95% CI =
163 0.99 to 4.69, $p = 0.06$), vomiting (OR= 2.0, 95% CI= 0.89 to 4.44, $p= 0.10$), diarrhoea (OR= 4.35,
164 95% CI = 1.908 to 9.610, $p= 0.0004$) or evidence of any fluid leakage (OR= 1.98, 95% CI = 0.91
165 to 4.5, $p = 0.11$) (table 10. They were also more likely to have a PCV rise of >20% from baseline
166 (OR= 1.87, 95% CI = 0.72 to 5.34, $p = 0.22$), compared to those who did not have bleeding.
167 Although there were no differences in the liver transaminase and C-reactive protein levels in
168 women who developed bleeding PV, vs those who did not, those who had bleeding PV were more
169 likely (OR= 1.92, 95% CI = 0.91 to 4.04, $p = 0.14$) to have a platelet count of <50,000 cells/mm³

170 (50%) than those who had no PV bleeding (34.6%). Interestingly, those who had PV bleeding were
 171 also more likely to have a positive NS1 antigen test (OR=1.84, 95% CI=0.59 to 5.17, p=0.33).

172

Clinical feature	Females who no had PV bleeding N= 260 (%)	Females who had PV bleeding N=28 (%)
Abdominal pain	90 (34.61)	15 (53.57)
Vomiting	104 (40)	16 (57.14)
Diarrhoea	76 (29.23)	18 (64.28)
Gall bladder oedema	104 (40)	16 (57.14)
Any evidence of fluid leakage	64 (24.61)	11 (39.28)
Pericholecystic fluid	55 (21.15)	11 (39.28)
Free Fluid in hepatorenal pouch	45 (17.30)	6 (21.42)
PCV increase from baseline		
5-10%	102 (39.23)	9 (32.14)
10-20%	82 (31.53)	9 (32.14)
>20%	25 (9.61)	5 (17.85)
Platelet counts		
>100,000	66 (25.38)	5 (17.85)
50,000-100,000	105 (40.38)	9 (32.14)
20,000-49,999	65 (25)	10 (35.71)
<20,000	25 (9.61)	4 (14.28)

AST		
<40	40 (15.38)	4 (14.28)
40-400	116 (44.61)	11 (39.28)
>400	15 (5.76)	0 (0)
ALT		
<40	81 (31.15)	9 (32.14)
40-400	131 (50.38)	13 (46.42)
>400	12 (4.61)	0 (0)
CRP		
<6	42 (16.15)	1 (3.57)
6 to 20	84 (32.30)	11 (39.28)
20-50	72 (27.69)	5 (17.85)
>50	25 (9.61)	2 (7.14)
Leucopenia	61 (23.46)	8 (28.57)
NS1 antigen positivity	159/224 (70.98)	18/22 (81.81)

173

174 **Table 1: Clinical and laboratory features of those who developed PV bleeding vs those who**
175 **had no bleeding manifestations**

176

177 **Complications and treatment received by those with bleeding PV compared to others**

178 As per standard care of this hospital, women who develop PV bleeding are given norethisterone
179 5mg three time a day and tranexamic acid 1g three times a day, until bleeding stops. The

180 differences in other standard of care and the treatment received in these two groups is shown in
181 table 2. Although not significant, those who had PV bleeding were more likely to have been given
182 IV fluids, blood transfusions, dextran and IV antibiotics.

183

Clinical feature	Females who had no PV bleeding N= 260 (%)	Females who had PV bleeding N=28 (%)	Odds ratio, 95% CI and p value
IV fluid given	172 (66.17%)	21 (75%)	1.53, 0.62 to 4.01, p= 0.40
Blood given	11 (4.23%)	3 (10.71%)	2.71, 0.76 to 9.99, p= 0.14
Dextran given	7 (2.69%)	2 (7.12%)	2.78, 0.55 to 13.79, p= 0.21
Duration of hospital stay (median, IQR)	3 (3 to 4)	4 (3 to 4.74)	p=0.43
IV antibiotics given	15 (5.76%)	3 (10.71%)	1.96, 0.56 to 6.43, p= 0.39

184

185 **Table 2: The treatment received by female patients with dengue who either had PV**
186 **bleeding or did not have any bleeding manifestations**

187

188

189 **Discussion**

190 In this study we sought to identify the frequency, risk factors and clinical outcomes in females
191 with dengue, who developed PV bleeding, compared to the women who had no bleeding
192 manifestations. We found that women who developed PV bleeding were more likely to have
193 dengue warning signs such as abdominal pain, persistent vomiting and plasma leakage. They were
194 also more likely to have a rise in PCV of $\geq 20\%$ from baseline and platelet counts of $\leq 50,000$
195 cells/mm³. Interestingly, although not considered a dengue warning sign, those who developed PV
196 bleeding were significantly more likely to have diarrhea. Although not significant, they were more
197 likely to require interventions such as blood transfusions, administration of dextran and
198 intravenous antibiotics. The women in our cohort who developed PV bleeding, did not have worse
199 disease outcomes, possibly as the standard of care in this hospital is to administer norethisterone
200 and tranexamic acid as soon as PV bleeding is detected. This practice could have led to women
201 with PV bleeding in this hospital, not having worse outcomes as reported elsewhere.

202

203 Although PV bleeding is a recognized complication of patients with dengue, the frequency and
204 associated clinical outcomes have not been described [15, 16, 19]. PV bleeding in dengue may
205 manifest as excessive bleeding in women who were menstruating at the time of illness, or
206 intermenstrual bleeding [19]. Female gender was found to be associated with a higher risk of
207 clinically significant bleeding, with 44.5% of those with clinically significant bleeding reporting
208 menorrhagia [20]. Therefore, the higher risk of severe disease in females reported in many studies,
209 could be due to PV bleeding [6, 13], although the reasons for classifying patients as having severe
210 dengue is not explained. There is lack of data of characterizing the extent of PV bleeding and its

211 possible contribution to disease outcomes in patients. For instance, a systematic review and
212 metanalysis, which had only four studies recording PV bleeding, showed that bleeding from the
213 gastrointestinal tract, pleural effusions, ascites and gall bladder wall thickening were significantly
214 associated with development of severe dengue, in patients with dengue warning signs [21].
215 Although PV bleeding was shown to associate with a moderate risk of severe dengue (odds ratio
216 6.62), this was not statistically significant [21]. Therefore, more data is needed to understand the
217 higher risk of severe dengue and mortality in females, with possible contribution of unrecognized
218 PV bleeding.

219

220 Bleeding per vagina in acute dengue is likely to be due to the increased bleeding diathesis, a
221 characteristic feature in dengue. Even though bleeding per vagina usually does not cause
222 significant volume depletion in a healthy person, it is likely to contribute to intravascular volume
223 depletion in a patient with plasma leakage. On the other hand, worsened bleeding diathesis in DHF
224 especially when there is significant volume depletion will aggravate bleeding per vagina leading
225 to a vicious cycle. Therefore, early identification of bleeding per vagina in dengue patients,
226 initiation of treatment to reduce bleeding and prevention of volume depletion, is of paramount
227 importance in reducing morbidity and mortality of dengue.

228

229 Dengue outbreaks have occurred in Sri Lanka for over three decades, with the number of cases
230 rising each year [4]. Despite the increase in number of cases, Sri Lanka has managed to gradually
231 reduce the CFRs from approximately 1% in 2009 to 0.05% by 2024 [4, 14]. Although a significant
232 reduction in CFRs has been achieved over the years by public health education to seek medical

233 care early, physician training programs for early detection of complications and meticulous and
234 timely fluid management, 22 individuals succumbed to their illness in 2024. Since 19/23 of those
235 who passed away are females, it would be important to understand the reasons for gender
236 discrepancies in mortality rates in Sri Lanka and the rest of the world, especially in women in the
237 reproductive age groups. Although gender differences in mortality have been observed with lower
238 mortality rates among females with sepsis and COVID-19 [22, 23], females appear to have higher
239 morbidity and mortality due to HIV [24]. Therefore, it would be important to conduct regular
240 mortality reviews and study epidemiological and immunological mechanisms that lead to higher
241 mortality in females with dengue, for understanding the causes of fatal dengue.

242

243 **Acknowledgments**

244 We are grateful to the NIH, USA (grant number 5U01AI151788-02) for funding.

245

246

247

248

249

250

251

252

253 **References**

- 254 1. Ten threats to global health in 2019 [Internet]. World Health Organization; 2019.
255 Available from: <https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019>
- 256 2. The L. Dengue: the threat to health now and in the future. *Lancet*. 2024;404(10450):311.
257 doi: 10.1016/S0140-6736(24)01542-3. PubMed PMID: 39067890.
- 258 3. Huang AT, Takahashi S, Salje H, Wang L, Garcia-Carreras B, Anderson K, et al.
259 Assessing the role of multiple mechanisms increasing the age of dengue cases in Thailand.
260 *Proceedings of the National Academy of Sciences of the United States of America*.
261 2022;119(20):e2115790119. Epub 20220509. doi: 10.1073/pnas.2115790119. PubMed PMID:
262 35533273; PubMed Central PMCID: PMCPMC9171776.
- 263 4. Malavige GN, Jeewandara C, Ghouse A, Somathilake G, Tissera H. Changing
264 epidemiology of dengue in Sri Lanka-Challenges for the future. *PLoS neglected tropical*
265 *diseases*. 2021;15(8):e0009624. Epub 2021/08/20. doi: 10.1371/journal.pntd.0009624. PubMed
266 PMID: 34411101; PubMed Central PMCID: PMCPMC8375976.
- 267 5. Gurgel-Goncalves R, Oliveira WK, Croda J. The greatest Dengue epidemic in Brazil:
268 Surveillance, Prevention, and Control. *Revista da Sociedade Brasileira de Medicina Tropical*.
269 2024;57:e002032024. Epub 20240920. doi: 10.1590/0037-8682-0113-2024. PubMed PMID:
270 39319953; PubMed Central PMCID: PMCPMC11415067.
- 271 6. Sangkaew S, Ming D, Boonyasiri A, Honeyford K, Kalayanarooj S, Yacoub S, et al. Risk
272 predictors of progression to severe disease during the febrile phase of dengue: a systematic
273 review and meta-analysis. *The Lancet infectious diseases*. 2021;21(7):1014-26. Epub 20210225.
274 doi: 10.1016/S1473-3099(20)30601-0. PubMed PMID: 33640077; PubMed Central PMCID:
275 PMCPMC8240557.

- 276 7. Paixao ES, Campbell OM, Teixeira MG, Costa MC, Harron K, Barreto ML, et al.
277 Dengue during pregnancy and live birth outcomes: a cohort of linked data from Brazil. *BMJ*
278 *Open*. 2019;9(7):e023529. Epub 20190724. doi: 10.1136/bmjopen-2018-023529. PubMed
279 PMID: 31345962; PubMed Central PMCID: PMC6661644.
- 280 8. Malavige GN, Ogg GS. Immune responses and severe dengue: what have we learned?
281 *Current opinion in infectious diseases*. 2024. Epub 20240725. doi:
282 10.1097/QCO.0000000000001040. PubMed PMID: 39079180.
- 283 9. Chagas GCL, Rangel AR, Noronha LM, Veloso FCS, Kassab SB, Oliveira MJC, et al.
284 Risk factors for mortality in patients with dengue: A systematic review and meta-analysis. *Trop*
285 *Med Int Health*. 2022;27(8):656-68. Epub 20220711. doi: 10.1111/tmi.13797. PubMed PMID:
286 35761748.
- 287 10. Mallhi TH, Khan AH, Sarriff A, Adnan AS, Khan YH. Determinants of mortality and
288 prolonged hospital stay among dengue patients attending tertiary care hospital: a cross-sectional
289 retrospective analysis. *BMJ Open*. 2017;7(7):e016805. doi: 10.1136/bmjopen-2017-016805.
290 PubMed PMID: 28698348; PubMed Central PMCID: PMC65724230.
- 291 11. Fonseca-Portilla R, Martinez-Gil M, Morgenstern-Kaplan D. Risk factors for
292 hospitalization and mortality due to dengue fever in a Mexican population: a retrospective cohort
293 study. *Int J Infect Dis*. 2021;110:332-6. Epub 20210728. doi: 10.1016/j.ijid.2021.07.062.
294 PubMed PMID: 34332086.
- 295 12. Anders KL, Nguyet NM, Chau NV, Hung NT, Thuy TT, Lien le B, et al. Epidemiological
296 factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in
297 Ho Chi Minh City, Vietnam. *The American journal of tropical medicine and hygiene*.

- 298 2011;84(1):127-34. Epub 2011/01/08. doi: 10.4269/ajtmh.2011.10-0476. PubMed PMID:
299 21212214; PubMed Central PMCID: PMC3005500.
- 300 13. Haider N, Asaduzzaman M, Hasan MN, Rahman M, Sharif AR, Ashrafi SAA, et al.
301 Bangladesh's 2023 Dengue outbreak - age/gender-related disparity in morbidity and mortality
302 and geographic variability of epidemic burdens. *Int J Infect Dis.* 2023;136:1-4. Epub 20230901.
303 doi: 10.1016/j.ijid.2023.08.026. PubMed PMID: 37660728.
- 304 14. National Dengue Control Unit MoH. Weekly Dengue Update. Week 47 (18th November
305 – 24rd November 2024). 2024.
- 306 15. Malavige GN, Jeewandara C, Wijewickrama A, Gunasinghe D, Mahapatuna SD,
307 Gangani C, et al. Efficacy of rupatadine in reducing the incidence of dengue haemorrhagic fever
308 in patients with acute dengue: A randomised, double blind, placebo-controlled trial. *PLoS*
309 *neglected tropical diseases.* 2022;16(6):e0010123. Epub 20220601. doi:
310 10.1371/journal.pntd.0010123. PubMed PMID: 35648794; PubMed Central PMCID:
311 PMC9191706.
- 312 16. Malavige GN, Wijewickrama A, Fernando S, Jeewandara C, Ginneliya A, Samarasekara
313 S, et al. A preliminary study on efficacy of rupatadine for the treatment of acute dengue
314 infection. *Sci Rep.* 2018;8(1):3857. doi: 10.1038/s41598-018-22285-x. PubMed PMID:
315 29497121; PubMed Central PMCID: PMC5832788.
- 316 17. Ariyaratne D GL, Jayadas TTP, Kuruppu H, Kodituwakku L, Jeewandara C, Panniahetti
317 N, Dheerasinghe A, Samaraweera S, Ogg G.S, Malavige G.N. Epidemiological and virological
318 factors determining dengue transmission in Sri Lanka during the COVID-19 pandemic. *PLOS*
319 *Glob Public Health.* 2022;2(8):e0000399. Epub August 3, 2022. doi:
320 <https://doi.org/10.1371/journal.pgph.0000399>.

- 321 18. WHO, editor. Comprehensive guidelines for prevention and control of dengue fever and
322 dengue haemorrhagic fever. SEARO, New Delhi, India: World Health Organization; 2011.
- 323 19. Tangnararatchakit K, Chuansumrit A, Chaiyaratana W, Lertwongrath S, Gajaseeni N,
324 Udomchaisakul R, et al. Excessive menstrual bleeding in adolescents with dengue infection. The
325 Pediatric infectious disease journal. 2010;29(1):92-3. doi: 10.1097/INF.0b013e3181bf5406.
326 PubMed PMID: 20035212.
- 327 20. Wong JG, Thein TL, Leo YS, Pang J, Lye DC. Identifying Adult Dengue Patients at Low
328 Risk for Clinically Significant Bleeding. PloS one. 2016;11(2):e0148579. doi:
329 10.1371/journal.pone.0148579. PubMed PMID: 26849556; PubMed Central PMCID:
330 PMCPMC4743958.
- 331 21. Htun TP, Xiong Z, Pang J. Clinical signs and symptoms associated with WHO severe
332 dengue classification: a systematic review and meta-analysis. Emerg Microbes Infect.
333 2021;10(1):1116-28. doi: 10.1080/22221751.2021.1935327. PubMed PMID: 34036893; PubMed
334 Central PMCID: PMCPMC8205005.
- 335 22. Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of
336 mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. Journal of
337 medical virology. 2020. doi: 10.1002/jmv.26050. PubMed PMID: 32441789.
- 338 23. Wanrooij VHM, Cobussen M, Stoffers J, Buijs J, Bergmans D, Zelis N, et al. Sex
339 differences in clinical presentation and mortality in emergency department patients with sepsis.
340 Ann Med. 2023;55(2):2244873. doi: 10.1080/07853890.2023.2244873. PubMed PMID:
341 37566727; PubMed Central PMCID: PMCPMC10424597.
- 342 24. Patwardhan V, Gil GF, Arrieta A, Cagney J, DeGraw E, Herbert ME, et al. Differences
343 across the lifespan between females and males in the top 20 causes of disease burden globally: a

- 344 systematic analysis of the Global Burden of Disease Study 2021. *Lancet Public Health*.
- 345 2024;9(5):e282-e94. doi: 10.1016/S2468-2667(24)00053-7. PubMed PMID: 38702093; PubMed
- 346 Central PMCID: PMCPMC11080072.
- 347